One of its important functions is acting as a free radical scavenger
As competition intensifies and new formulations move through regulatory and clinical milestones, the GLP-1 market is poised to remain a major driver of growth and innovation across the broader pharmaceutical industry
They classify it as an unfair hormone-releasing hormone analog
Category-wise Analysis By Product, Ozempic Dominates the GLP-1 Receptor Agonist Market Ozempic (semaglutide) dominates with 32.1% share of the global market in 2025 , due to its strong efficacy in both glycemic control and weight management
This overlap makes determining whether observed cases represent a true drug effect or reflect underlying patient susceptibility challenging
Some patients find success by rotating medicationspausing semaglutide and switching to tirzepatide (a dual GLP-1/GIP agonist), which engages additional appetite and metabolic pathways, can reignite weight loss in sensitive patients
:max_bytes(150000):strip_icc()/GettyImages-2126120280-94c8334d07474c6883f6bb568b95693f.jpg)
